Outlook Therapeutics (OTLK) announced that the National Institute for Health and Care Excellence, NICE, has recommended LYTENAVA, as an option ...

Mr. Kenyon has served as the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as ...

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010 (Lytenava) to treat patients with wet age-related ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91.

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...